Fintel reports that on October 10, 2025, Morgan Stanley maintained coverage of Vertex Pharmaceuticals (NasdaqGS:VRTX) with a Equal-Weight recommendation. Analyst Price Forecast Suggests 18.17% Upside ...
Preclinical data presented at the European Society of Gene and Cell Therapy (ESGCT) highlight a potential best-in-class profile--The AATD ...
Treating pain has long been a challenge. Over-the-counter treatments often don’t do enough, while opioids block pain signals ...
Vertex Pharmaceuticals has been a clear winner in the pharmaceutical sector. Over the past two decades, this powerhouse has ...
Looking at options history for Vertex Pharmaceuticals (NASDAQ: VRTX) we detected 10 trades. If we consider the specifics of ...
Vertex Pharmaceuticals’ CRISPR-based therapy made history as the first drug of its type, transforming care options for sickle ...
Now, it’s worth noting Stock Advisor's total average return is 1,061% — a market-crushing outperformance compared to 192% for ...
As the industry loses one of its key female leaders in GSK CEO Emma Walmsley, BioSpace profiles the women leading the ...
All of this means that, trading at 22 times forward earnings estimates, down from more than 27 times earlier this year, ...
Ian Smith, the former chief financial officer of Vertex Pharmaceuticals, has taken over as CEO of Stoke Therapeutics.
ClearBridge Investments, an investment management company, released its “ClearBridge Large Cap Growth Strategy” third-quarter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback